🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Pioglitazone

    Takeda

    HIV-Associated Lipodystrophy Syndrome

    phase 3 small molecule terminated

    1 trial

  2. Pioglitazone and Azilsartan

    Takeda

    Type 2 Diabetes

    phase 3 small molecule terminated

    1 trial

  3. Pioglitazone and Glimepiride

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  4. Pioglitazone, EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE, GLIMEPIRIDE, GLICLAZIDE, METFORMIN HYDROCHLORIDE, GLIPIZIDE, METFORMIN HYDROCHLORIDE, EMPAGLIFLOZIN, GLIQUIDONE, Placebo for Actos 15 mg tablets, METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

    Celltrion Healthcare Australia Pty Ltd

    Type 2 diabetes mellitus (T2DM)

    phase 3 small molecule active

    1 trial

  5. Pioglitazone-Azilsartan

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

  6. Pitolisant

    Harmony Biosciences Holdings

    Prader-Willi Syndrome

    phase 3 small molecule active

    1 trial

  7. Pitolisant

    Harmony Biosciences Holdings

    Idiopathic Hypersomnia

    phase 3 small molecule completed

    1 trial

  8. Pitolisant tablet

    Harmony Biosciences Holdings

    Prader-Willi Syndrome

    phase 3 small molecule active

    1 trial

  9. Placebo

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  10. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 small molecule completed

    1 trial

  11. Placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Postpartum Depression

    phase 3 small molecule completed

    2 trials

  12. Placebo

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis VI

    phase 3 small molecule completed

    1 trial

  13. Placebo

    Agios Netherlands B.V.

    Pyruvate Kinase Deficiency

    phase 3 small molecule completed

    1 trial

  14. Placebo

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  15. Placebo

    Takeda

    Male Subjects With Chronic Constipation

    phase 3 small molecule completed

    1 trial

  16. Placebo

    Biogen

    Multiple Sclerosis, Remittent Progressive

    phase 3 small molecule completed

    1 trial

  17. Placebo

    NEUROCRINE BIOSCIENCES INC

    Dyskinesia

    phase 3 small molecule completed

    1 trial

  18. Placebo

    AstraZeneca

    Irritable Bowel Syndrome With Constipation (IBS-C)

    phase 3 small molecule completed

    1 trial

  19. Placebo

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Erectile Dysfunction

    phase 3 small molecule completed

    1 trial

  20. Placebo

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  21. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Adult Attention Deficit Hyperactivity Disorder

    phase 3 small molecule completed

    1 trial

  22. Placebo

    Allergan Pharmaceuticals International Limited

    Gastroparesis

    phase 3 small molecule terminated

    3 trials

  23. Placebo

    United Therapeutics Europe Ltd

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule completed

    1 trial

  24. Placebo

    Mineralys Therapeutics

    Hypertension

    phase 3 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources